Regen Biologics' collagen meniscus implant shows promise in early studies, CEO says.
This article was originally published in The Gray Sheet
ReGEN BIOLOGICS' COLLAGEN MENISCUS IMPLANT FEASIBILITY STUDY resulted in seven of nine patients describing their knees as "nearly normal" after treatment with the implant, ReGen Chief Executive Officer Michael Egan reported at the Hambrecht & Quist life sciences conference in San Francisco. In addition, seven of nine patients showed "marked improvement from their pre-op status," and all patients returned to activities of daily living with minimal or no pain.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.